PMID- 11991242
OWN - NLM
STAT- MEDLINE
DCOM- 20021219
LR  - 20191105
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 8
IP  - 1
DP  - 2002 Jan
TI  - Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin 
      on hemostatic properties of endothelium.
PG  - 65-71
AB  - Human endothelial cells synthesize and secrete a variety of molecules involved in 
      fibrinolysis and coagulation. The effects of a low molecular weight heparin, 
      Bemiparin, and unfractionated heparin (UFH) were compared on plasminogen 
      activator inhibitor-1 (PAI-1), tissue-plasminogen activator (t-PA), tissue factor 
      (TF), tissue factor pathway inhibitor (TFPI) release, and PAI-1 gene expression 
      by human umbilical vein endothelial cells (HUVEC). Cell cultures were 
      supplemented with Bemiparin or UFH at 1 or 10 U/mL. Culture media samples were 
      obtained before the addition of the drugs and 2, 6, and 24 hours afterward to 
      measure the antigen levels of TF, TFPI, t-PA, and PAI-1. RNA was obtained to 
      study the endothelial expression of PAI-1 by reverse transcriptase-polymerase 
      chain reaction (RT-PCR). Bemiparin at 1 U/mL resulted in a decreased messenger 
      RNA (mRNA) PAI-1 expression, which remained unaltered when UFH had been added. 
      PAI-1 levels increased after the cultures had been supplemented with either 
      Bemiparin or UFH at both doses. UFH induced an increase in t-PA either at 1 or 10 
      U/mL. Both doses of UFH, but not Bemiparin, induced an important increase in TF 
      secretion. An increase in the TFPI levels was seen with UFH at 1 U/mL. The 
      decrease in PAI-1 gene expression observed with a therapeutic dose of Bemiparin 
      might confer this drug interesting profibrinolytic properties. The fact that 
      Bemiparin, in contrast with UFH, does not induce an increase in TF could give 
      this drug another positive feature.
FAU - Perez-Ruiz, Ana
AU  - Perez-Ruiz A
AD  - Haemostasis and Thrombosis Research Unit, School of Medicine, University of 
      Navarra, Pamplona, Spain.
FAU - Montes, Ramon
AU  - Montes R
FAU - Carrasco, Pilar
AU  - Carrasco P
FAU - Rocha, Eduardo
AU  - Rocha E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Lipoproteins)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 9005-49-6 (Heparin)
RN  - 9035-58-9 (Thromboplastin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - PUE0TO3XDR (bemiparin)
SB  - IM
MH  - Anticoagulants/*pharmacology
MH  - Cells, Cultured/drug effects/physiology
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Fibrinolysis
MH  - Gene Expression Regulation/drug effects
MH  - Heparin/*pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Humans
MH  - Lipoproteins/analysis
MH  - Plasminogen Activator Inhibitor 1/analysis/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Thromboplastin/analysis
MH  - Tissue Plasminogen Activator/analysis/metabolism
MH  - Umbilical Veins
EDAT- 2002/05/07 10:00
MHDA- 2002/12/20 04:00
CRDT- 2002/05/07 10:00
PHST- 2002/05/07 10:00 [pubmed]
PHST- 2002/12/20 04:00 [medline]
PHST- 2002/05/07 10:00 [entrez]
AID - 10.1177/107602960200800109 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2002 Jan;8(1):65-71. doi: 10.1177/107602960200800109.